Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V-stabilizing fab.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Efficacy and safety of point-of-care ultrasound-guided intra-articular corticosteroid joint injections in patients with haemophilic arthropathy.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Coated platelet assay: a feasible approach to a complicated science.

Haemophilia : the official journal of the World Federation of Hemophilia·2015
Same author

Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?

Haemophilia : the official journal of the World Federation of Hemophilia·2015
Same author

Early hemostatic responses to trauma identified with hierarchical clustering analysis.

Journal of thrombosis and haemostasis : JTH·2015

Related Experiment Video

Updated: May 13, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Monitoring rFVIII prophylaxis dosing using global haemostasis assays.

M A Al Hawaj1, E J Martin, J Venitz

  • 1Coagulation Advancement Laboratory, Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA 23298-0533, USA.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|March 21, 2013
PubMed
Summary

Secondary factor VIII (FVIII) prophylaxis improves haemophilia but FVIII levels alone don't predict bleeding. Thrombin generation assay (TGA) better reflects coagulation status than thromboelastography (TEG) over 48 hours, aiding individualized prophylaxis.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Related Experiment Videos

Last Updated: May 13, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Area of Science:

  • Hematology
  • Coagulation Science
  • Pharmacokinetics

Background:

  • Secondary factor VIII (FVIII) prophylaxis transforms severe hemophilia (FVIII:C < 1 IU dL(-1)) to a moderate phenotype (FVIII:C ≥ 1 IU dL(-1)).
  • Plasma FVIII:C levels are insufficient predictors of bleeding risk in patients with hemophilia.
  • Current prophylaxis regimens may not fully capture individual bleeding phenotypes.

Purpose of the Study:

  • To quantify coagulation dynamics using thromboelastography (TEG) and thrombin generation assay (TGA) during a 48-hour recombinant FVIII (rFVIII) prophylaxis period.
  • To evaluate the correlation between FVIII:C levels and global coagulation assay parameters.
  • To assess the sensitivity of TEG and TGA in reflecting bleeding risk and FVIII:C levels.

Main Methods:

  • Ten severe hemophilia patients received standard rFVIII prophylaxis.
  • Blood samples were collected over 48 hours to measure FVIII:C, TEG, and TGA.
  • Pharmacokinetic (PK) analysis of FVIII:C and correlation analyses between global assays were performed.

Main Results:

  • FVIII:C PK parameters were consistent with existing literature.
  • Significant correlations were observed between FVIII:C and TEG R-time, aPTT, and TGA parameters (peak, ETP, velocity).
  • TEG showed sub-therapeutic parameters at 24 hours despite adequate FVIII:C; TGA remained sensitive to FVIII:C < 1 IU dL(-1) and correlated with bleeding phenotype severity, while TEG lost sensitivity at 48 hours.

Conclusions:

  • Thrombin generation assay (TGA) demonstrates greater sensitivity than TEG in reflecting FVIII:C levels and bleeding risk over 48 hours.
  • TGA may be a more reliable tool for assessing coagulation status in hemophilia patients undergoing prophylaxis.
  • Further prospective studies are warranted to explore individualized rFVIII prophylaxis regimens based on TGA and TEG data.